ArticleToxins2023
Trends in Botulinum Toxin Use among Patients with Multiple Sclerosis: A Population-Based Study.
Article in Toxins, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Evolution of Drug Development Trends in Multiple Sclerosis: Analysis of Mainland China and Global Landscapes From 2004 to 2024.CNS neuroscience & therapeutics · 2026Article
- Trends and off-label use of botulinum toxin type A in Chinese neurological practice from 2016 to 2023: a real-world study.Frontiers in pharmacology · 2026Article
- Botulinum toxin A for post-stroke spasticity: Insights from the French National Hospital Discharge Database (2015-2023).European stroke journal · 2026Article
- Botulinum Toxin Underuse in Older Stroke Survivors with Spasticity: A Nationwide Population-Based Cohort Study.Neuroepidemiology · 2025Article
- Botulinum toxin A for post-stroke spasticity: Insights from the French National Hospital Discharge Database (2015-2023).European stroke journal · 2025Article
- Spasticity Management with Botulinum Toxin in Post-stroke and Multiple Sclerosis Patients: A Retrospective, 'Real-world', Multicenter Study.NeuroRehabilitation · 2025Observational
- Clinical Insights and Radiological Features on Multiple Sclerosis Comorbid with Migraine.Journal of clinical medicine · 2025Review
- Real-World Use of Intradetrusor Botulinum Toxin Injections: A Population-Based Study from France.Toxins · 2024Article
- Article
- Botulinum Neurotoxins: From Toxin to Medicine.Toxins · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are limited real-world data on the use of botulinum toxin type A (BoNT-A) in patients with multiple sclerosis (MS). Accordingly, this nationwide, population-based, retrospective cohort study aimed to describe BoNT-A treatment trends in patients with MS between 2014 and 2020 in France. This study extracted data from the French National Hospital Discharge Database (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.